Bourdage Sets Out Sandoz’ Biosimilar Growth Ambitions

Adding At Least One Molecule Per Year But Maintaining ‘Selective’ Approach

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Sandoz plans to add at least one new molecule per year to its biosimilar development plans, while still maintaining a “selective” approach to targets, head of biopharmaceuticals Pierre Bourdage explains in the second part of an exclusive interview with Generics Bulletin.

Future years to 2030 2040 pin
Biosimilars are expected to be a $5bn-$6bn business for Sandoz by 2030 • Source: Alamy

After discussing global biosimilars regulation and market dynamics in the first part of his exclusive interview with Generics Bulletin (Also see "Sandoz’s Bourdage Makes Case For Tailored Biosimilar Pathways" - Generics Bulletin, 22 June, 2021.), Sandoz’ head of biopharmaceuticals, Pierre Bourdage, has set out the firm’s strategy to build up its own biosimilars business into a unit worth $5bn-$6bn by 2030.

“Biosimilars are a strategically important area for [parent company] Novartis and a key growth driver for Sandoz and Novartis,” Bourdage...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C6

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.